DBV Technologies S.A.

NasdaqCM:DBVT Voorraadrapport

Marktkapitalisatie: US$973.8m

DBV Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

DBV Technologies heeft een totaal eigen vermogen van $207.9M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $266.4M en $58.5M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$229.20m
AandelenUS$207.90m
Totaal verplichtingenUS$58.50m
Totaal activaUS$266.40m

Recente financiële gezondheidsupdates

Recent updates

Seeking Alpha • Sep 21

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

French biotech DBV Technologies (NASDAQ:DBVT) on Wednesday said the U.S. FDA had put a partial clinical hold on its phase 3 clinical study evaluating its Viaskin Peanut patch for the treatment of peanut allergy in children aged 4 through 7. The FDA specified certain changes to elements of the protocol of the trial, called VITESSE. "Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data, to meet study objectives as well as the total number of trial participants on active treatment," DBVT said in a statement. The company had not yet begun the screening or recruitment of subjects in the study. DBVT said the partial clinical hold was only for the VITESSE trial and did not impact any other ongoing clinical studies. U.S.-listed shares of DBVT earlier closed +4.3% at $2.21.
Seeking Alpha • Aug 01

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

DBV Technologies press release (NASDAQ:DBVT): Q2 GAAP EPS of -$0.35 misses by $0.03. Revenue of $1.53M beats by $0.29M. Shares +3.19% AH.
Seeking Alpha • Jul 07

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient. The company previously received a CRL due to issues with the adhesion properties of their patch. The Phase 3 EPITOPE trial met the primary endpoint with a good safety profile. FDA feedback on the regulatory path is the next critical catalyst for the company. DBV Technologies (DBVT) is developing an epicutaneous (on the skin) delivery system for the treatment of food allergies including peanuts and milk. After completing a Phase 3 trial in children ages 4-11, the company received a CRL from the FDA for their Viaskin peanut patch due to concerns about patch adhesion. The company redesigned the patch and will need to run a new Phase 3 trial using the modified patch for this age group. Recently, using the unmodified patch, the EPITOPE study met the primary endpoint in children ages 1-4. DBV Technologies is well capitalized after a recent raise that occurred after the EPITOPE readout. There is considerable uncertainty about the regulatory path but longer term these assets, if approved have significant value. Peanut Allergies and Treatment Options There are more than one million children in the US with peanut allergies. The prevalence in babies is increasing and as many as 5% of babies have a peanut allergy. Avoidance of peanuts is the primary strategy but accidental exposure can result in severe reactions. Allergy treatments gradually increase the quantity of allergen that a child is exposed to. The goal of treatment is to desensitize the child and increase the quantity of peanut that elicits an allergic reaction. There are no FDA-approved treatments for peanut allergies in children ages 1-3. At age 4, children would become eligible for Palforzia which is an oral immunotherapy. It is newly approved and can only be prescribed by a trained allergist and requires an FDA mandated risk mitigation plan due to the risk of anaphylaxis. In the Palforzia program, under the supervision of a trained physician, children ingest increasing amounts of peanut protein. Dose escalation occurs in a certified physician’s office. At dose escalation, 67 % of patients reported abdominal pain, 36.5% experienced vomiting, 32% reported nausea and 31% reported oral itching. There was a 9.4 % rate of anaphylaxis during dose escalation and 8.7% during maintenance dosing. At the end of treatment, 67% of Palforzia patients could tolerate a 600 mg dose of peanuts. (600 mg is approximately 2 peanuts). The EPITOPE study met the primary endpoint Toddlers aged 1-3 who have a peanut allergy were enrolled in the clinical trial. On a daily basis, their caregivers applied a Viaskin peanut patch. The patch at the highest dose contains 250 micrograms of peanut protein which is a very, very small amount of peanut protein. (A microgram is one thousandth of an mg.) The EPITOPE trial was one year in duration. 244 toddlers received treatment and 118 received placebo. At baseline and at the end of treatment, toddlers received a food challenge to determine their eliciting dose. The eliciting dose is the amount of peanut that causes allergic symptoms. At the end of treatment, patients who were successfully treated made the improvements shown in the chart below. Before Treatment After Treatment Eliciting dose less than or equal to 10 mg Eliciting dose greater than or equal to 300 mg Eliciting dose greater than 10 mg Eliciting dose greater than or equal to 1000 mg Source: DBV Technologies 67% of children treated met the "success" response criteria at 12 months. In comparison, 33.5 % of placebo treated children met the endpoint. (Note: The placebo response was likely a result of a self resolving peanut allergy.) This result was statistically significant and the primary endpoint was met. In the trial, there was one SAE which was swelling around the eye. The most common side effect was a reaction at the site where the patch was applied. 22.5 % of the children experienced a site reaction that was severe as compared to 8.5% of placebo patients. These reactions decreased during the one year treatment period. Eight children discontinued treatment due to side effects. Four children (1.6%) treated with Viaskin Peanut experienced an anaphylactic reaction that was determined to be or may have been related to treatment. None of these anaphylactic reactions were serious. Three of these reactions resolved with epinephrine and one without epinephrine. A long term open label extension study is underway. Revenue Projections

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $246.7M ) DBVT } overtreffen de korte termijn passiva ( $51.8M ).

Langlopende schulden: De kortetermijnactiva DBVT ( $246.7M ) overtreffen de langetermijnschulden ( $6.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: DBVT is schuldenvrij.

Schuld verminderen: DBVT heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 0.6% was.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: DBVT heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: DBVT heeft minder dan een jaar aan kasmiddelen beschikbaar als de vrije kasstroom blijft groeien met een historisch percentage van 6.8 % per jaar.

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/08 18:43
Aandelenkoers aan het einde van de dag2026/07/08 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

DBV Technologies S.A. wordt gevolgd door 16 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Tazeen AhmadBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC